Keyword: Endo

Stability has finally returned to the U.S. generics market, which had been suffering what Teva CEO Kåre Schultz called “a classical negative death spiral."

Philadelphia's city council is considering legislation to regulate pharma reps including prohibiting any gifts to healthcare providers and staff.

Endo’s lawsuit to keep the FDA from giving bulk compounders the ability to compete with one of its key drugs is off for now.

Staring at 1,000 opioid lawsuits, Endo is said to be trying to negotiate its own settlement deal with lawyers for states and cities.

AndroGel plaintiffs and drugmaker AbbVie have progressed in settlement talks, and a judge stayed further proceedings so they can work out a deal.

Endo Pharmaceuticals is expanding its awareness campaign for Peyronie’s disease after seeing an increase in Xiaflex sales.

Trump's request comes as the DOJ and DEA propose to cut production quotas for the six most frequently misused opioids by 10% next year.

Dr. Reddy's moved ahead with an "at risk" launch of Indivior's top drug, but now a court has put the rollout on hold.

Endo moved to resolve "all known" testosterone drug lawsuits it faced. The company last year set aside $200 million for the litigation.

India's Aurobindo has submitted a $1.6 billion offer for Novartis' generic dermatology assets in the U.S., according to Livemint.